About 100 early-phase clinical trials and investigator-led studies of targeted antivascular
therapies—both anti-angiogenic and vascular-targeting agents—have reported data derived …

A greater understanding of non–small-cell lung cancer at a molecular level has led to the
identification of an increasing number of driver mutations. Extensive research of the KRAS …

Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study
showed the recommended dose of 750 mg/day with substantial antitumor activity. This …

Tumor response assessment has been a foundation for advances in cancer therapy. Recent
discoveries of effective targeted therapy for specific genomic abnormalities in lung cancer …

Lung cancer remains the leading cause of cancer-related deaths in both men and women.
However, the discovery of several oncogenic driver mutations and the development of …

Purpose: Several case reports suggest sorafenib exposure and sorafenib-induced
hyperbilirubinemia may be related to a (TA) 5/6/7 repeat polymorphism in UGT1A1* 28 …

The efficacy of anti-VEGF agents probably lies on VEGF-dependency. Apatinib, a specific
tyrosine kinase inhibitor that targets VEGF receptor 2, was assessed in patients with …

Background The prognostic and predictive value of KRAS mutations in patients with lung
cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient …

Purpose To examine the correlations between uni-dimensional RECIST and volumetric
measurements in patients with lung adenocarcinoma and to assess their association with …

Introduction The incidence of mesothelioma is rising. First-line cisplatin and pemetrexed
confers a survival benefit, with a median progression-free survival (PFS) of 5.7 months …